Central to Washington University in St. Louis’ mission of fostering excellence in research is a commitment to ensure that all individuals responsible for the design, conduct and reporting of research involving human participants receive education in the protection of those participants that is appropriate and adequate to assure the ethical conduct of the research.

The goal of this policy is to provide a framework to resolve allegations of research misconduct as rapidly and fairly as possible and to protect the rights and integrity of all individuals involved.

Our institutional responsibility requires that any investigational drug or device is used in the manner intended by the research project, is stored under appropriate controlled conditions, and is used only by (on) subjects who have consented to participate in the research project.

Infection control procedures for areas supporting both animal and human studies

All research involving human participants must be reviewed and approved by WashU’s duly appointed Institutional Review Board or another IRB where WashU has entered into a reliance agreement to defer oversight.

WashU publishes these guidelines to support investigators engaged in human embryonic stem cell research, assure the responsible conduct of human embryonic stem cell research and comply with federal, state and local laws and regulations.

WashU faculty and staff who execute clinical trials subject to the FDA policy, the NIH policy, or the ICMJE policy should register (or ensure the registration of) all trials as required.

Billings to customers should be done in a timely and regular manner after services/products have been provided.